Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MorningSun: Subcutaneous Mosunetuzumab Monotherapy in Select B-Cell Malignancies
NCT05207670Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Feb 2022
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab in non-Hodgkin lymphoma (NHL), sponsored by Genentech. Started Feb 2022; status: active, not recruiting.
02
Drugs
mosunetuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05207670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207670.